Locally Recurrent Lung Non-Small Cell Carcinoma
1 clinical trials · Condition
◉ Watch Locally Recurrent Lung Non-Small Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial (NCT03801902) | National Cancer Institute (NCI) | 2019-10-28 |
Track Locally Recurrent Lung Non-Small Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.